Use of mesenchymal stem cells or their culture supernatant

Culturing MSCs with imidazole dipeptide in a serum-free medium produces a culture supernatant and cells that enhance disease suppression and inhibit osteogenic differentiation, addressing the limitations of conventional MSC culture supernatants.

JP7873894B2Inactive Publication Date: 2026-06-15CELL EXOSOME THERAPEUTICS INC
View PDF 5 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
CELL EXOSOME THERAPEUTICS INC
Filing Date
2025-02-13
Publication Date
2026-06-15
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The composition of conventional mesenchymal stem cell (MSC) culture supernatants requires improvement for effective disease suppression or improvement, and existing methods do not adequately inhibit osteogenic differentiation.

Method used

Culturing MSCs in a medium containing imidazole dipeptide, either with or without serum, to produce a culture supernatant or cells that suppress or improve diseases, inhibit osteogenic differentiation, and promote the expression of specific cytokines and exosome secretion.

Benefits of technology

The method yields a culture supernatant and MSCs that effectively suppress or improve diseases by enhancing cytokine concentrations and inhibit osteogenic differentiation, with improved safety profiles and enhanced cytokine expression.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007873894000005
    Figure 0007873894000005
  • Figure 0007873894000006
    Figure 0007873894000006
  • Figure 0007873894000007
    Figure 0007873894000007
Patent Text Reader

Abstract

To provide a culture supernatant of mesenchymal stem cells or mesenchymal stem cells, containing components secreted from cells such as cytokines, useful for suppressing or improving disease; a pharmaceutical composition comprising mesenchymal stem cells; and a method for producing a pharmaceutical composition.SOLUTION: A culture supernatant of mesenchymal stem cells contains at least 500 pg / mL of G-CSF and at least 2700 pg / mL of IL-6. The culture supernatant preferably contains an imidazole dipeptide, and preferably further contains at least 670 pg / mL of TGF-β1, at least 3.5 pg / mL of IL-7, or at least 6500 pg / mL of IL-8.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Serum-free culture medium of primary umbilical cord mesenchymal stem cells and use method thereof

    CN109777771A

  • Method for producing proteins using anti-aging compounds

    JP2010524504A

  • Technique for culture of mesenchymal stem cell utilizing laminin-5

    WO2007023875A1

  • Culture media and methods for culturing mesenchymal stem cell

    WO2007123363A1

  • Method for producing proliferating cells, method for producing cell product, mesenchymal stem cell population and method for producing same, culture supernatant of stem cells and method for producing same, and therapeutic agent

    WO2021200744A1